Idera Pharmaceuticals, Inc. (IDRA): Price and Financial Metrics


Idera Pharmaceuticals, Inc. (IDRA): $0.44

0.03 (+8.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IDRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IDRA Stock Price Chart Interactive Chart >

Price chart for IDRA

IDRA Price/Volume Stats

Current price $0.44 52-week high $1.71
Prev. close $0.41 52-week low $0.30
Day low $0.38 Volume 3,279,100
Day high $0.45 Avg. volume 778,935
50-day MA $0.47 Dividend yield N/A
200-day MA $0.71 Market Cap 23.55M

Idera Pharmaceuticals, Inc. (IDRA) Company Bio


Idera Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. The company was founded in 1989 and is based in Cambridge, Massachusetts.


IDRA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDRA Latest Social Stream


Loading social stream, please wait...

View Full IDRA Social Stream

Latest IDRA News From Around the Web

Below are the latest news stories about Idera Pharmaceuticals Inc that investors may wish to consider to help them evaluate IDRA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 15, 2021

Idera Pharmaceuticals'' stock tanks after AbbVie cuts enrollment early in a PhIb trial

When Idera Pharmaceuticals flunked a Phase III melanoma trial with its Toll-like receptor 9 agonist tilsotolimod back in March, executives clung to the hope that separate trials in other cancers would turn up better results. Without the results it was hoping for, Idera says its now discontinuing enrollment in a

Endpoints News | December 15, 2021

Idera Pharmaceuticals Announces Tilsotolimod Updates

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, and our) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.

Intrado Digital Media | December 14, 2021

State Street Corp Grows Stock Position in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

State Street Corp raised its holdings in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) by 437.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 109,744 shares of the biotechnology companys stock after acquiring an additional 89,334 shares during the quarter. State Street Corps holdings in Idera Pharmaceuticals were worth $132,000 as of its most recent SEC []

Dakota Financial News | December 12, 2021

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. “We are maintaining our focus on identifying new development or commercial-stage assets for Idera’s portfolio and we are encouraged by the opportunities presented to us,” stated Vincent Milano, Idera’s Chief Executive Officer. “As a number of these prospects adva

Yahoo | November 8, 2021

Read More 'IDRA' Stories Here

IDRA Price Returns

1-mo -9.33%
3-mo -9.61%
6-mo -36.42%
1-year -58.88%
3-year -83.14%
5-year -96.80%
YTD -22.81%
2021 -84.47%
2020 101.65%
2019 -34.30%
2018 -83.59%
2017 40.67%

Continue Researching IDRA

Want to see what other sources are saying about Idera Pharmaceuticals Inc's financials and stock price? Try the links below:

Idera Pharmaceuticals Inc (IDRA) Stock Price | Nasdaq
Idera Pharmaceuticals Inc (IDRA) Stock Quote, History and News - Yahoo Finance
Idera Pharmaceuticals Inc (IDRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8918 seconds.